FIGURE 2.

The change of CD27, CD69 and CD86 expression during ibrutinib treatment. Relative expression levels of three markers (CD27 (black line), CD69 (dotted line) and CD86 (dashed line)) and the CLL ratio (grey line) were analysed during ibrutinib treatment in a patient’s peripheral blood sample who ultimately became ibrutinib resistant (Clin. res.). We used the initial expression levels (day 0) of the CD27, CD69 and CD86 as a benchmark. The time point when the tendency has changed level marked by a vertical dotted line. When the markers’ expression exceeded the benchmark level marked by a vertical dashed line.